Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed ...

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

NHS advisors have again rejected pleas for potentially life-saving routine prostate cancer screening after concluding that ...

Only men with a specific gene variant and a family history of certain cancers should be screened, experts have said.

The majority of men in the UK will not be offered prostate cancer screening following a final recommendation from a committee ...

Low testosterone may increase the risk of aggressive prostate cancer progression during active surveillance. Learn more about the findings.

Government will consider committee’s guidance that says mass screening ‘likely to cause more harm than good’ ...

Among men with high-risk localized prostate cancer, those receiving neoadjuvant apalutamide combination therapy had improved potency recovery by 12 months and reduced rates of positive margins ...

The UK's National Screening Committee has concluded its review of prostate cancer screening in the UK, saying that the harms of a large-scale, national programme would outweigh the benefits. The ...

New research has found that low testosterone levels can cause extreme progression in high-grade prostate cancer. The study ...

Majority of men in UK will not be offered routine prostate cancer screening - Black men have double the risk of prostate ...